Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab vs Oral Prophylactics in Episodic Migraine (APPRAISE)
NCT03927144Phase 4Completed
- Sponsor
- Amgen
- Start
- May 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 4, randomised, open-label trial in episodic migraine comparing Erenumab Arm with Standard of Care Arm (2 arms). Primary endpoint: Number of Participants Who Completed Initially Assigned Treatment and Achieved at Least a 50% Reduction From Baseline in Monthly Migraine Days at Month 12. Started May 2019; status: completed.
02
Drugs
erenumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03927144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927144.